Cargando…
Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
BACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314638/ https://www.ncbi.nlm.nih.gov/pubmed/28209203 http://dx.doi.org/10.1186/s40644-017-0109-5 |
_version_ | 1782508556882280448 |
---|---|
author | Cameron, Laird B Jiang, Damian H S Moodie, Kate Mitchell, Catherine Solomon, Benjamin Parameswaran, Bimal Kumar |
author_facet | Cameron, Laird B Jiang, Damian H S Moodie, Kate Mitchell, Catherine Solomon, Benjamin Parameswaran, Bimal Kumar |
author_sort | Cameron, Laird B |
collection | PubMed |
description | BACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - rearranged advanced non-small cell lung cancer (NSCLC) treated with Crizotinib. Many of these lesions undergo spontaneous resolution despite developing complex features on imaging. We assess the incidence and patterns of evolution of Crizotinib Associated Renal Cysts [CARCs] at our institute and provide histopathology correlation of their benign nature. METHODS: A retrospective analysis of renal lesions in computerised tomography (CT) scans of 35 patients with advanced ALK-rearranged NSCLC who had been prescribed crizotinib at our institution was performed by three radiologists, who analysed the evolution of these lesions, particularly for pre-defined significant and complex changes. RESULTS: Of 26 patients eligible for this analysis, 4 (15%) had cysts at baseline that remained stable on crizotinib treatment while 11(42%) developed significant change in 28 renal cysts. Commonest pattern of cyst evolution was enlargement from baseline followed by spontaneous regression (17/28 lesions) while other patterns noted were stable lesions, regression from baseline and ongoing enlargement. The median maximum size reached was 23 mm (range 9 – 67 mm) after a median of 178 days (160 to 1342) on crizotinib. Complex change occurred in 12 cysts, in 7/26 (27%) patients and within 60 days of starting Crizotinib in 10 cysts. Imaging features were falsely concerning for malignancy or abscess in 4/26 patients. CONCLUSION: Most CARCs resolve spontaneously, or have a benign evolution despite enlargement and other features concerning for malignancy or infection on imaging. This unusual manifestation of chemotherapy should be recognised, particularly by radiologists, so that inappropriate treatment decisions are avoided. |
format | Online Article Text |
id | pubmed-5314638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53146382017-02-24 Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution Cameron, Laird B Jiang, Damian H S Moodie, Kate Mitchell, Catherine Solomon, Benjamin Parameswaran, Bimal Kumar Cancer Imaging Research Article BACKGROUND: Novel therapeutic agents recently introduced for the treatment of cancer have several unusual side effects. An increased incidence of renal cystic lesions, often with features concerning for malignancy or infection, has been reported in patients with anaplastic lymphoma kinase (ALK) - rearranged advanced non-small cell lung cancer (NSCLC) treated with Crizotinib. Many of these lesions undergo spontaneous resolution despite developing complex features on imaging. We assess the incidence and patterns of evolution of Crizotinib Associated Renal Cysts [CARCs] at our institute and provide histopathology correlation of their benign nature. METHODS: A retrospective analysis of renal lesions in computerised tomography (CT) scans of 35 patients with advanced ALK-rearranged NSCLC who had been prescribed crizotinib at our institution was performed by three radiologists, who analysed the evolution of these lesions, particularly for pre-defined significant and complex changes. RESULTS: Of 26 patients eligible for this analysis, 4 (15%) had cysts at baseline that remained stable on crizotinib treatment while 11(42%) developed significant change in 28 renal cysts. Commonest pattern of cyst evolution was enlargement from baseline followed by spontaneous regression (17/28 lesions) while other patterns noted were stable lesions, regression from baseline and ongoing enlargement. The median maximum size reached was 23 mm (range 9 – 67 mm) after a median of 178 days (160 to 1342) on crizotinib. Complex change occurred in 12 cysts, in 7/26 (27%) patients and within 60 days of starting Crizotinib in 10 cysts. Imaging features were falsely concerning for malignancy or abscess in 4/26 patients. CONCLUSION: Most CARCs resolve spontaneously, or have a benign evolution despite enlargement and other features concerning for malignancy or infection on imaging. This unusual manifestation of chemotherapy should be recognised, particularly by radiologists, so that inappropriate treatment decisions are avoided. BioMed Central 2017-02-16 /pmc/articles/PMC5314638/ /pubmed/28209203 http://dx.doi.org/10.1186/s40644-017-0109-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Cameron, Laird B Jiang, Damian H S Moodie, Kate Mitchell, Catherine Solomon, Benjamin Parameswaran, Bimal Kumar Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution |
title | Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution |
title_full | Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution |
title_fullStr | Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution |
title_full_unstemmed | Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution |
title_short | Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution |
title_sort | crizotinib associated renal cysts [carcs]: incidence and patterns of evolution |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5314638/ https://www.ncbi.nlm.nih.gov/pubmed/28209203 http://dx.doi.org/10.1186/s40644-017-0109-5 |
work_keys_str_mv | AT cameronlairdb crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution AT jiangdamianhs crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution AT moodiekate crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution AT mitchellcatherine crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution AT solomonbenjamin crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution AT parameswaranbimalkumar crizotinibassociatedrenalcystscarcsincidenceandpatternsofevolution |